A revolutionary approach in the treatment of cancer. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach in cancer treatment. It involves extracting immune cells, specifically T cells, from a patient’s tumor tissue. These T cells are then grown and multiplied in a laboratory before being reintroduced into the patient’s body. The goal is to enhance the immune system’s ability to recognize and attack cancer cells effectively. TIL therapy is …

Read more

  This article closely examines cancer clinical trials in China in the past few years, focusing on major findings and areas of progress. It also discusses newly approved cancer drugs in China, examining their mechanism of action, efficacy from trials, potential side effects, and speculation on access and affordability. Cancer is the biggest cause of death in China, with more than 4.5 million new cases diagnosed each year. Recognizing the …

Read more

Introduction Since chimeric antigen receptor (CAR) T cell therapy came out, oncology has seen a dramatic shift in cancer treatment. This innovative approach harnesses the power of the immune system to fight cancer. It has shown remarkable results in certain types of blood cancer, giving hope to people who are facing limited treatment options. The rapid rise of CAR T cell therapy in China is a paradigm shift in cancer …

Read more

In recent years, China has emerged as a global leader in the development of novel medical technology, particularly cellular therapies. Among these discoveries, chimeric antigen receptor (CAR) T cell therapy stands out as a promising treatment for certain tumors. CAR T cell treatment is taking a patient's immune cells, altering them in a lab to better target cancer cells, and then returning them into the patient's body to combat the …

Read more

Liver Cancer Liver cancer, specifically hepatocellular carcinoma (HCC), poses a substantial healthcare obstacle on a global scale, since its occurrence rates have been consistently increasing in recent years. Although there have been improvements in traditional treatments, the outlook for advanced liver cancer is still unfavorable, which means that it is important to investigate new and creative therapeutic methods. Out of these options, CAR T cell therapy has emerged as a …

Read more

Tumor-infiltrating lymphocyte (TIL) therapy treatment is a potential method that utilizes the body’s immune system to fight solid tumors. This therapeutic area in China is advancing rapidly because of the nation’s increasing investment in cell therapy and gene editing businesses, despite being relatively young. TIL therapy in China encounters problems such as inadequate infrastructure, the absence of established protocols, and an insufficient understanding of optimal patient selection and treatment combinations. The …

Read more

        According to a recent study published in Nature Medicine, blood from patients can be used to screen circulating tumor DNA (ctDNA) and can provide insights about the success of therapy and if any course correction is required   Want to do something impactful for cancer immunotherapy research? Your contribution can help fuel the future of cancer treatment and care. Donate today to the Cancer Research Institute   The Cancer …

Read more

2024 has been a game-changer for CAR T-Cell therapy in China! Witness remarkable success stories from clinical trials, explore advancements, and learn about the remaining challenges. Come discover the future of this ground-breaking cancer treatment that is giving millions of people hope again!   Science has made remarkable growth in the field of medicine. In the last few years, we have seen many innovative therapies and drugs that act as …

Read more

This article closely examines cancer clinical trials in China in the past few years, focusing on major findings and areas of progress. It also discusses newly approved cancer drugs in China, examining their mechanism of action, efficacy from trials, potential side effects, and speculation on access and affordability.   Cancer is the biggest cause of death in China, with more than 4.5 million new cases diagnosed each year. Recognizing the …

Read more

The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA’s approval marks a turning point in China’s fight against multiple myeloma. This blog explores the effectiveness of this therapy, its safety, and its potential to improve patient outcomes. Dive in and learn more about FUCASO and the hope it brings for refractory multiple myeloma patients. Multiple myeloma, a blood cancer that affects plasma cells, can …

Read more